In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
In this interview, Theodoros Teknos, MD, a Professor at The Ohio State University Medical School and Chairman for the Department of Otolaryngology (Head & Neck Surgery) at the Ohio State University Medical Center /James Cancer Hospital, sat down with the OncoTherapy Network to discuss the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
These results were also presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7, 2016, in Chicago (abstract 6036).
Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer
March 5th 2024Patients with factors such as lymphovascular space invasion or positive glossectomy specimen margins may be considered for adjuvant radiotherapy to optimize disease control of tongue squamous cell carcinoma.
Pembrolizumab/Lenvatinib Combo Shows Mixed Results in Recurrent/Metastatic HNSCC
March 1st 2024Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.